Tag Archives: Lundbeck

Lundbeck, Rgenta Therapeutics partner over discovery of small molecules targeting RNA regulation and splicing of disease-causing genes

(PRESS RELEASE) VALBY, 4-Aug-2021 — /EuropaWire/ — Lundbeck (CPH: LUN), a Danish international pharmaceutical company, has announced it will partner with Rgenta Therapeutics, Cambridge, MA-based developer of oral, small-molecule RNA-targeting medicines with an initial focus on oncology, to discover small … Read the full press release

Lundbeck commits to become carbon neutral across the entire value chain by 2050

(PRESS RELEASE) COPENHAGEN, 4-Feb-2021 — /EuropaWire/ — Danish international pharmaceutical company H. Lundbeck A/S (Lundbeck) announces its new 15-year climate target, which includes a detailed action plan to reduce emissions, approved by the Science Based Targets initiative (SBTi), towards becoming … Read the full press release

Lundbeck welcomes acceptance of Vyepti’s marketing authorization application by the European Medicines Agency for the prevention of migraine

(PRESS RELEASE) VALBY, Denmark, 22-Dec-2020 — /EuropaWire/ — Danish international pharmaceutical company, H. Lundbeck A/S (Lundbeck) announces that its marketing authorization application for Vyepti™ (eptinezumab-jjmr) has been accepted by the European Medicines Agency (EMA). The filing seeks approval to introduce … Read the full press release

Lundbeck begins clinical development of yet another potential new treatment of Parkinson’s disease

New treatment might have the potential to slow or stop the progression of Parkinson’s disease. VALBY, 12-Sep-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the … Read the full press release

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announce European Commission approval for Rxulti® (brexpiprazole) for the treatment of schizophrenia in adults

Rxulti® (brexpiprazole) has been approved for the treatment of schizophrenia in adults. VALBY, 01-Aug-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the European Commission has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia … Read the full press release

Lundbeck to further optimize its commercial structure to improve its ability to launch new medicines

Lundbeck aims to further improve its ability to launch new medicines through a new commercial structure. The initiative could lead to a reduction of around 50-55 positions in Europe. Valby, 21-6-2013 — /europawire.eu/ — H. Lundbeck A/S (Lundbeck) plans to further … Read the full press release

EC Vice-President Joaquín Almunia comments on Lundbeck anticompetitive agreements case

Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines: statement by Vice-President Almunia Joaquín Almunia – Vice President of the European Commission responsible for Competition Policy Press conference, Brussels, 21-6-2013 — /europawire.eu/ — Today the European Commission has found … Read the full press release

H. Lundbeck A/S disappointed and strongly disagrees with EC decision and intends to appeal

The European Commission has decided that Lundbeck’s agreements concluded with four generic competitors concerning citalopram violated competition law The decision includes fining Lundbeck EUR 93 million Lundbeck’s financial guidance for 2013 is maintained excluding costs connected to the fine Lundbeck is … Read the full press release

EC fines Danish pharmaceutical company Lundbeck over anticompetitive agreements

Brussels, 20-6-2013 — /europawire.eu/ — The European Commission has imposed a fine of € 93,8 million on Danish pharmaceutical company Lundbeck and fines totalling € 52,2 million on several producers of generic medicines. In 2002, Lundbeck agreed with each of these … Read the full press release